20WAYS TO IMPROVE PATIENT CARE & PHARMACY COST CONTAINMENT Extended Oral BUD Studies in Pursuit of Scientific Progress by MEDISCA WINTER 2014 I HEALTH SYSTEM • INFUSION 51 President & CEO: Antonio Dos Santos Founded: 1989 Employees: 300 Toll-free Phone: (800) 932-1039 Fax: (855) 850-5855 Address: MEDISCA 661 Route 3, Unit C Plattsburgh, NY 12901 USA Website: www.medisca.com Prolong the life and efficacy of compounded oral preparations using MEDISCA’s dye-free oral vehicles. The main Objective of MEDISCA’s BUD initiative is to raise safety awareness and standardize new or existing pediatric formulations. Company Background In only 20 years, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry. We are dedicated to providing the highest quality products and supplies, unparalleled service and competitive pricing to our clients located around the world. Together with our educational arm, MEDISCA NETWORK, we offer a full complement of continuing pharmacy educational training activities. Initiative Overview The continuous pursuit of scientific progress has been the primary focus of MEDISCA which has taken shape in the investment and support of stability-indicating studies for pharmacy compounding. Accurate results ensure that a medication has maintained its strength and stability in a compounded dosage form. MEDISCA is working with prominent research institutions to build a comprehensive BUD (Beyond Use Date) databank not only for drugs which lack stability data, but also for commonly compounded drugs which lack a dye-free alternative. n Unique Aspects of Our Current Oral BUD Studies • Target 90 day BUD using DYE-FREE oral bases. • Studies conducted using validated stability indicating assays. • Tested at room temperature and refrigerated conditions to evaluate effect of temperature on stability. • Include variable container closures to determine optimal storage conditions. • Involve commonly compounded API’s and API’s lacking stability data. • Performed in collaboration with renowned institutions and researchers. • Published in peer reviewed pharmaceutical journals such as the Canadian Journal of Hospital Pharmacy (CJHP). Features & Options The extended BUD stability results are currently available for the following APIs. Each formulation was prepared in MEDISCA’S Oral vehicles and was studied at variable temperature and in a variety of containers. • Clonidine 0.01mg/mL • Dexamethasone Phosphate 1mg/mL • Pyridoxine 25mg/mL • Amlodipine 1mg/mL • Enalapril 1mg/mL • Prednisone 5mg/mL • Tacrolimus 0.5mg/mL • Clobazam 1mg/mL • Nadolol 10mg/mL And the list is still growing … Product Specifications Conveniently formulated, MEDISCA’s line of oral vehicles aims to ease the preparation of extemporaneous dosage forms even when dietary restrictions are of a concern. Providing pharmacists with five DYE-FREE oral vehicles, elegant and physically stable suspensions are to be expected. Testimonial “After evaluating the stability of our first few compounded preparations using MEDISCA’s Oral Mix, I am pleased with the end results. The suspensions achieved a nice consistency with good redispersibility and stability profile. We will continue to study other drugs in these vehicles.” — Karen Walsh Compounding Pharmacist The Hospital for Sick Children Toronto, Canada
20Ways Winter2014 Hospital Edition
To see the actual publication please follow the link above